Patents Assigned to Genzyme Corporation
  • Patent number: 9579343
    Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 28, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Joseph Tyler, John S. Petersen
  • Patent number: 9579325
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 28, 2017
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Patent number: 9580511
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 28, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Publication number: 20170042979
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Application
    Filed: October 18, 2016
    Publication date: February 16, 2017
    Applicant: Genzyme Corporation
    Inventor: James STEFANO
  • Patent number: 9567382
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Patent number: 9556155
    Abstract: The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 31, 2017
    Assignee: Genzyme Corporation
    Inventors: Hongmei Zhao, Nelson S. Yew, Seng H. Cheng, Canwen Jiang, Cynthia Marie Arbeeny
  • Patent number: 9555056
    Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 31, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
  • Patent number: 9546161
    Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: January 17, 2017
    Assignee: Genzyme Corporation
    Inventors: Bradford H. Hirth, Craig Siegel
  • Publication number: 20170007719
    Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize gene delivery to human eyes of soluble Flt-1 receptors, as well fusion proteins including a soluble Flt-1 receptor.
    Type: Application
    Filed: February 6, 2015
    Publication date: January 12, 2017
    Applicant: Genzyme Corporation
    Inventor: Abraham Scaria
  • Patent number: 9539325
    Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 10, 2017
    Assignee: Genzyme Corporation
    Inventors: Jay Harper, Scott Lonning, Frank Hsu
  • Patent number: 9532976
    Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 3, 2017
    Assignee: Genzyme Corporation
    Inventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
  • Patent number: 9528126
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 9518049
    Abstract: The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 13, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Craig S. Siegel, Jin Zhao
  • Patent number: 9506083
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: November 29, 2016
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Patent number: 9498518
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 22, 2016
    Assignee: GENZYME CORPORATION
    Inventor: James Stefano
  • Patent number: 9498528
    Abstract: A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favorable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ?12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: November 22, 2016
    Assignees: GENZYME CORPORATION, ALCAFLEU MANAGEMENT GMBH & CO. KG.
    Inventors: David H. Margolin, Walter Hong, Alasdair J. Coles, Alastair Compston, Ze'ev Shaked
  • Patent number: 9493498
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 15, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 9492415
    Abstract: Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 15, 2016
    Assignees: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Janet Cunningham
  • Patent number: D775324
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 27, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Robin Cameron Larson, Barbara Yu-Fong Wan, Daniel John Zuniga, Manikandan Namasivayam, Leticia Fabiano, Frederic Daniel Blanquaert, Anthony John Franchino, Jr.
  • Patent number: D775325
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 27, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Robin Cameron Larson, Barbara Yu-Fong Wan, Daniel John Zuniga, Manikandan Namasivayam, Leticia Fabiano, Frederic Daniel Blanquaert, Anthony John Franchino, Jr.